Article Text

other Versions

Download PDFPDF
Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results
  1. Shaun S Tan,
  2. Ka Lip Chew,
  3. Sharon Saw,
  4. Roland Jureen,
  5. Sunil Sethi
  1. 1Department of Laboratory Medicine, National University Hospital, Singapore
  1. Correspondence to Dr Shaun S Tan, National University Hospital, Singapore 119074, Singapore; shaun_sy_tan{at}nuhs.edu.sg

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

HIV may be considered as a differential diagnosis for patients who present with prolonged fever and respiratory symptoms. During the COVID-19 pandemic, several patients from our institution have had a simultaneous screening test for serum HIV antigen/antibodies as well as a nasopharyngeal swab for SARS-CoV-2 real-time reverse transcription PCR (rRT-PCR) on presentation to the hospital. While the molecular results often have a delayed turnaround time in light of increased testing volume, HIV screen performed as a chemiluminescent immunoassay on our Abbott Architect platform (Abbott Laboratories, Abbott Park, Illinois, USA) has a testing time of only 30 min. Herein, we retrospectively reviewed and identified two positive COVID-19 cases on rRT-PCR who concurrently tested reactive for HIV on the Architect, with further confounding results.

Both patients were admitted and tested in the same month. Our first patient was a man in his early 20s who had no significant medical history, presenting with a persistent fever for 2 days, dry cough and pharyngitis. He was not on any long-term medications. His initial laboratory investigations revealed white …

View Full Text

Footnotes

  • Handling editor Tahir S Pillay.

  • Contributors SST and KLC drafted the initial manuscript. SSa, RJ, SSe critically reviewed and approved of final submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The institutional ethics review board approved our study (DSRB: 2020/00407).

  • Provenance and peer review Not commissioned; internally peer reviewed.